Edoxaban: Considerable added benefit for certain patients

November 5, 2015, Institute for Quality and Efficiency in Health Care

Edoxaban (trade name: Lixiana) has been approved since June 2015 for two therapeutic indications in adults: on the one hand, for prevention of stroke and systemic embolism in adults with non-valvular atrial fibrillation (NVAF) with other risk factors for stroke; on the other, for treatment and prevention of deep vein thrombosis and pulmonary embolism. The German Institute for Quality and Efficiency in Health Care (IQWiG) examined in a dossier assessment whether this drug offers an added benefit over the appropriate comparator therapy.

In conclusion, an indication of considerable added benefit in comparison with vitamin K antagonists was derived for the of stroke and : Stroke, bleeding and severe side effects occurred less frequently under edoxaban. For the second therapeutic indication, suitable analyses were lacking in the drug manufacturer dossier.

Comparison with warfarin in both therapeutic indications

In compliance with the approval, IQWiG assessed edoxaban in two separate modules: firstly for prevention of stroke and systemic embolism in patients with NVAF with at least one other risk factor for stroke, such as hypertension, prior stroke, or diabetes mellitus (assessment module I); secondly for the treatment of deep and , and to prevent recurrent thrombosis and pulmonary embolism (assessment module II).

The Federal Joint Committee (G-BA) specified vitamin K antagonists (VKAs) as appropriate comparator therapy for both therapeutic indications. In its dossier, the manufacturer compared edoxaban with warfarin in each case.

Positive effects in the prevention of stroke and embolism

Major bleeding was less frequent in the total population of study participants who were taking edoxaban. Some advantages of edoxaban for different outcomes were only shown in women: They had fewer haemorrhagic strokes, fewer nonmajor bleeding events requiring treatment, and fewer severe side effects than the comparator group. Fewer disabling strokes occurred in patients with a high risk of stroke (CHADS2 score > 3).

Overall, only positive effects of edoxaban in the prevention of and systemic embolism remain. The probability of added benefit or lesser harm regarding several symptoms and complaints (morbidity) as well as is "indication"; the extent varies from "considerable" to "minor" (see assessment module I).

No separate analyses according to treatment duration

In the second therapeutic indication, the treatment and prevention of (recurrent) and pulmonary embolism, a distinction has to be made between two patient populations that require different treatment durations: either acute and temporarily limited prevention of three to six months, or continuous prevention for longer than three to six months (long-term prevention). However, the manufacturer did not distinguish between these two patient populations in its dossier, and presented no separate analyses for the respective patient group (see assessment module II). Hence there are no suitable analyses for an assessment in this therapeutic indication, and no hint of an added benefit can be derived.

Explore further: Apixaban in atrial fibrillation: Indications of considerable added benefit

More information: www.iqwig.de/download/A15-29_E … ertung-35a-SGB-V.pdf

Related Stories

Apixaban in atrial fibrillation: Indications of considerable added benefit

August 2, 2013
The clot-inhibiting drug apixaban (trade name: Eliquis) has been approved in Germany since November 2012 for the prevention of embolism and stroke in adults with non-valvular atrial fibrillation. In an early benefit assessment ...

Nivolumab in melanoma: Added benefit in certain patients

October 20, 2015
Nivolumab (trade name: Opdivo) has been approved since June 2015 for adults with advanced melanoma. The German Institute for Quality and Efficiency in Health Care (IQWiG) examined in a dossier assessment whether this drug ...

Secukinumab in plaque psoriasis: Manufacturer dossier provided no hint of an added benefit

September 8, 2015
Secukinumab (trade name: Cosentyx) has been approved since January 2015 for adults with moderate to severe plaque psoriasis. The German Institute for Quality and Efficiency in Health Care (IQWiG) examined in a dossier assessment ...

Fingolimod in RRMS: Indication of added benefit in certain patients

July 6, 2015
Pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) reassessed fingolimod (trade name: Gilenya), a drug for the treatment ...

Belatacept after a kidney transplant: Indication of considerable added benefit

October 21, 2015
Belatacept (trade name: Nulojix) has been approved since June 2011 for adults after a kidney transplant. It is used together with other drugs to prevent the body from rejecting the transplanted organ. After a first early ...

Proof of added benefit of apixaban in hip replacement

September 17, 2012
The clot-inhibiting drug apixaban (trade name: Eliquis) was approved in May 2011 for the prevention of thrombosis (blood clots) after operations to replace a hip or knee joint. In an early benefit assessment pursuant to the ...

Recommended for you

New wave of complex street drugs puzzles emergency doctors

August 21, 2018
At a time when drug overdoses are becoming more prevalent and lethal, a new report provides a snapshot of regional illicit drug use and, for the first time, highlights the complexity of detecting and treating patients at ...

Study finds racial disparities in prescribing opioids for chronic pain

August 20, 2018
Yale researchers have identified racial disparities in the treatment of patients who are prescribed opioids for chronic pain. Black patients who receive opioids long-term are more likely than whites to be tested for illicit ...

Proposal seeks to improve assessment of drug risks

August 20, 2018
A drug policy researcher is proposing a suite of changes to overhaul the Multi-Criteria Drug Harm Scale (MCDHS), which informs drug policies across Europe. The changes focus on addressing use and abuse separately, collecting ...

US approves first generic competitor to Mylan's EpiPen

August 16, 2018
US regulators Thursday approved the first generic alternative for the EpiPen, a life-saving emergency allergy medicine, two years after soaring prices for the original version owned by Mylan stoked controversy.

Study: What patients really think about opioid vs non-opioid medications for chronic pain

August 14, 2018
Prescriptions of opioids for chronic pain has increased dramatically since the 1990s in spite of their known harms. Despite a shortage of scientific studies on the long-term effectiveness of opioids such as morphine, oxycodone ...

Doctors nudged by overdose letter prescribe fewer opioids

August 9, 2018
In a novel experiment, doctors got a letter from the medical examiner's office telling them of their patient's fatal overdose. The response: They started prescribing fewer opioids.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.